TCGA-MT-A51W-01A-21R-A266-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.720
- INTERFERON_GAMMA_RESPONSE+0.560
- TNFA_SIGNALING_VIA_NFKB+0.460
- OXIDATIVE_PHOSPHORYLATION+0.350
- P53_PATHWAY+0.340
- MYC_TARGETS_V1+0.330
- ESTROGEN_RESPONSE_LATE+0.310
- IL6_JAK_STAT3_SIGNALING+0.310
- MYC_TARGETS_V2+0.290
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.290
Top 10 suppressed
- ANGIOGENESIS-0.380
- MYOGENESIS-0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.240
- PANCREAS_BETA_CELLS-0.200
- HEDGEHOG_SIGNALING-0.120
- UV_RESPONSE_DN-0.120
- SPERMATOGENESIS-0.080
- KRAS_SIGNALING_UP-0.040
- BILE_ACID_METABOLISM-0.030
- UNFOLDED_PROTEIN_RESPONSE-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-7099-01A-41R-2016-07 | — | — | 0.882 |
| 2 | TCGA-CV-7089-01A-11R-2016-07 | — | — | 0.846 |
| 3 | TCGA-E7-A7XN-01A-11R-A352-07 | — | — | 0.834 |
| 4 | BS_GJNCYABP | ATRT | — | 0.815 |
| 5 | TCGA-XF-AAN2-01A-11R-A42T-07 | — | — | 0.812 |
| 6 | TCGA-CQ-6220-01A-11R-1915-07 | — | — | 0.812 |
| 7 | SRR1313147 | — | E | 0.811 |
| 8 | 8f1213be-da41-4cd6-97b2-f9fce1ea00ff | — | — | 0.808 |
| 9 | c340b651-bd01-4194-a67b-e801d0feeb2b | — | — | 0.807 |
| 10 | TCGA-P3-A6T7-01A-11R-A34R-07 | — | — | 0.794 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.720 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.560 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.460 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.340 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.310 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.280 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.230 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.220 | Remibrutinib | — uncovered |
| HYPOXIA | 0.220 | Idelalisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |